Tacrolimus as Secondary Intervention vs. Continuation of Cyclosporine in Renal Transplant Patients With Chronic Renal Allograft Failure (CRAF)

Inclusion Criteria: * Patient is at least 3 months post-transplant of a cadaveric or living donor kidney * Patient has been on a cyclosporine-based immunosuppression regimen since the transplant * Patient has one of the following risk factors for chronic renal allograft failure at the baseline biopsy: * Serum creatinine: Male: \>=2.0mg/dL (176.8 umol/L); Female: \>= 1.7mg/dL (150.28 umol/L) 3 months or later post-transplant * Serum creatinine \> 30% increased over post-discharge nadir * Patient has had a renal biopsy \> 3 months after transplant and within 6 months prior to enrollment * Patient or legal guardian has signed and dated an IRB approved informed consent document * Female patient has a negative pregnancy test and agrees to practice effective birth control while receiving mycophenolate mofetil (MMF) Exclusion Criteria: * Patient is dialysis dependent and has recurrence of primary or de novo renal disease * Patient has an estimated creatinine clearance \<25mL/min * Patient has changed maintenance immunosuppressant therapy (e.g., azathioprine to MMF) within 3 months of randomization * Baseline biopsy shows acute rejection Grade \>=IIB using Banff 95 criteria or \>= Grade IIA using Banff 97 criteria * Patient requires antilymphocyte therapy to treat rejection at baseline or post-baseline biopsy * Patient has received an investigational immunosuppressant within 3 months, or has a known hypersensitivity to tacrolimus, or any excipients of the drug * Patient is a known carrier of any of the HIV viruses